tradingkey.logo
tradingkey.logo
Buscar

Twist Bioscience Corp

TWST
Añadir a la lista de seguimiento
49.170USD
-3.780-7.14%
Cierre 05/15, 16:00ETCotizaciones retrasadas 15 min
3.06BCap. mercado
PérdidaP/E TTM

Twist Bioscience Corp

49.170
-3.780-7.14%

Más Datos de Twist Bioscience Corp Compañía

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

Información de Twist Bioscience Corp

Símbolo de cotizaciónTWST
Nombre de la empresaTwist Bioscience Corp
Fecha de salida a bolsaOct 31, 2018
Director ejecutivoLeproust (Emily M)
Número de empleados979
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 31
Dirección681 Gateway Blvd.
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono18007190671
Sitio Webhttps://www.twistbioscience.com/
Símbolo de cotizaciónTWST
Fecha de salida a bolsaOct 31, 2018
Director ejecutivoLeproust (Emily M)

Ejecutivos de Twist Bioscience Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
398.19K
-1.29%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
99.15K
+5.14%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
69.20K
-4.11%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
52.14K
-3.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
28.78K
+17.70%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
26.07K
-4.28%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
20.75K
-7.23%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
13.28K
+21.80%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
13.14K
-73.06%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
398.19K
-1.29%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
99.15K
+5.14%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
69.20K
-4.11%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
52.14K
-3.76%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
28.78K
+17.70%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
26.07K
-4.28%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
NGS applications
52.64M
50.76%
DNA synthesis and protein solutions
51.06M
49.24%
Por regiónUSD
Nombre
Ganancia
Proporción
Americas
58.38M
56.30%
EMEA
38.37M
37.00%
APAC
6.95M
6.70%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
NGS applications
52.64M
50.76%
DNA synthesis and protein solutions
51.06M
49.24%

Estadísticas de accionistas

Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Artisan Partners Limited Partnership
10.23%
ARK Investment Management LLC
10.19%
EdgePoint Investment Group Inc.
8.64%
William Blair Investment Management, LLC
8.46%
BlackRock Institutional Trust Company, N.A.
7.71%
Otro
54.78%
Accionistas
Accionistas
Proporción
Artisan Partners Limited Partnership
10.23%
ARK Investment Management LLC
10.19%
EdgePoint Investment Group Inc.
8.64%
William Blair Investment Management, LLC
8.46%
BlackRock Institutional Trust Company, N.A.
7.71%
Otro
54.78%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
64.84%
Investment Advisor/Hedge Fund
35.76%
Hedge Fund
8.42%
Research Firm
5.50%
Pension Fund
1.72%
Individual Investor
1.41%
Bank and Trust
0.59%
Family Office
0.16%
Insurance Company
0.03%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
592
78.48M
126.03%
-339.29K
2025Q4
585
73.72M
120.24%
-3.30M
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Artisan Partners Limited Partnership
6.22M
10.14%
+387.01K
+6.64%
Feb 27, 2026
ARK Investment Management LLC
7.56M
12.33%
+832.69K
+12.38%
Dec 31, 2025
EdgePoint Investment Group Inc.
5.38M
8.77%
+1.30M
+31.74%
Dec 31, 2025
William Blair Investment Management, LLC
5.95M
9.71%
+1.81M
+43.75%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
4.80M
7.83%
-12.17K
-0.25%
Dec 31, 2025
State Street Investment Management (US)
3.63M
5.92%
+538.75K
+17.44%
Dec 31, 2025
Soleus Capital Management, L.P.
1.86M
3.04%
-4.43K
-0.24%
Dec 31, 2025
Goldman Sachs & Company, Inc.
1.50M
2.45%
+189.78K
+14.49%
Dec 31, 2025
Ver más

ETFs relacionados

Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
ARK Genomic Revolution ETF
6.24%
iShares Genomics Immunology and Healthcare ETF
3.92%
Global X Genomics & Biotechnology ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2%
WisdomTree BioRevolution Fund
1.79%
ARK Innovation ETF
1.47%
Franklin Genomic Advancements ETF
1.17%
State Street SPDR S&P Biotech ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.66%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
Ver más
ARK Genomic Revolution ETF
Proporción6.24%
iShares Genomics Immunology and Healthcare ETF
Proporción3.92%
Global X Genomics & Biotechnology ETF
Proporción2.09%
ROBO Global Healthcare Technology & Innovation ETF
Proporción2%
WisdomTree BioRevolution Fund
Proporción1.79%
ARK Innovation ETF
Proporción1.47%
Franklin Genomic Advancements ETF
Proporción1.17%
State Street SPDR S&P Biotech ETF
Proporción0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.66%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.56%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI